Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Sep 26, 2013 10:10 AM Flag

    Negative technical pattern ends

    Looks like IMGN is a buy on dips now, $17.5 is the next critical level. It's frustrating to see stocks like CLDX and SGEN kicking IMGN's rear in performance and market cap, especially CLDX which has not proven their technology as far as I have seen. Hopefully patience and agitation will eventually be rewarded in a big way. Shorting IMGN seems really ignorant unless one is managing a hedge fund that's long SGEN and CLDX and short IMGN.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I'm growing impatient with this stock. I know a lot of folks on this message board have a sunny forecast for IMGN in 2014. If it drops down into the 15's again I may punt.

      • 2 Replies to denial_of_death
      • Imunogen is a wound spring. I agree with Bioimmuno. Just have to be very, very patient.

        Sentiment: Buy

      • many investors are growing impatient. I have emailed (through linked-in) multiple members of the BOD several times this year asking for a change in the executive management of IMGN. They never respond, but we did get one change and I am hopeful, more change is coming. IMGN should have updates on most of their 10 compounds (internal and partnered) over the next year except for the most exciting 289. I am hopeful 289 will eventially achieve breakthrough status, but that might require a very well defined patient population and diagnostic, which has not been a strength for IMGN. You have to decide if you are an investor, or a trader. If you are a trader, follow the technicals and trade it. If you want in interesting biotech that appears to be a "value" with limited downside (due to Kadcyla) and strong upside potential, IMGN is the best candidate I know about.

 
IMGN
13.75-0.28(-2.00%)Jun 3 4:00 PMEDT